GOLDMAN SACHS GROUP INC - TRILLIUM THERAPEUTICS INC ownership

TRILLIUM THERAPEUTICS INC's ticker is and the CUSIP is 89620X506. A total of 130 filers reported holding TRILLIUM THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of TRILLIUM THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$22,191,000
+356.2%
1,263,721
+152.0%
0.01%
+400.0%
Q2 2021$4,864,000
+340.6%
501,442
+387.4%
0.00%
Q1 2021$1,104,000
-86.7%
102,875
-81.8%
0.00%
-100.0%
Q4 2020$8,326,000
+229.9%
566,042
+218.8%
0.00%
+200.0%
Q3 2020$2,524,000
+54.6%
177,561
-12.0%
0.00%
Q2 2020$1,633,000
+258.9%
201,833
+79.2%
0.00%
Q1 2020$455,000112,6510.00%
Other shareholders
TRILLIUM THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Opaleye Management Inc. 260,000$5,260,0002.44%
Avoro Capital Advisors LLC 160,697$3,234,0001.24%
Private Capital Advisors, Inc. 83,820$1,696,0000.62%
Monashee Investment Management LLC 25,000$506,0000.32%
SPHERA FUNDS MANAGEMENT LTD. 95,000$1,922,0000.20%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 226,064$4,573,0000.15%
Spark Investment Management LLC 36,700$745,0000.10%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 29,121$589,0000.04%
A.R.T. Advisors, LLC 15,480$313,0000.01%
Tower Research Capital LLC (TRC) 1,200$31,0000.00%
View complete list of TRILLIUM THERAPEUTICS INC shareholders